Innoviva (INVA) Competitors

Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.

Do institutionals & insiders believe in INVA or BCRX?

99.1% of Innoviva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in INVA or BCRX?

BioCryst Pharmaceuticals received 193 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 67.16% of users gave BioCryst Pharmaceuticals an outperform vote while only 57.52% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Innoviva	Outperform Votes 306 57.52%	Underperform Votes 226 42.48%
BioCryst Pharmaceuticals	Outperform Votes 499 67.16%	Underperform Votes 244 32.84%

Does the media refer more to INVA or BCRX?

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for BioCryst Pharmaceuticals and 10 mentions for Innoviva. Innoviva's average media sentiment score of 1.42 beat BioCryst Pharmaceuticals' score of 1.10 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend INVA or BCRX?

Innoviva currently has a consensus target price of $55.00, suggesting a potential upside of 190.70%. BioCryst Pharmaceuticals has a consensus target price of $16.56, suggesting a potential upside of 59.28%. Given Innoviva's stronger consensus rating and higher possible upside, equities analysts plainly believe Innoviva is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
BioCryst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Which has more risk and volatility, INVA or BCRX?

Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Is INVA or BCRX more profitable?

Innoviva has a net margin of 18.31% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Innoviva's return on equity of 20.84% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	18.31%	20.84%	11.38%
BioCryst Pharmaceuticals	-30.01%	N/A	-24.06%

Which has higher earnings and valuation, INVA or BCRX?

Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$369.84M	3.21	$179.72M	-$1.01	-18.73
BioCryst Pharmaceuticals	$503.49M	4.32	-$226.54M	-$0.26	-39.98

Summary

Innoviva and BioCryst Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.